These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 8080038)
1. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Bhargava V; Kell DL; van de Rijn M; Warnke RA Am J Pathol; 1994 Sep; 145(3):535-40. PubMed ID: 8080038 [TBL] [Abstract][Full Text] [Related]
2. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882 [TBL] [Abstract][Full Text] [Related]
3. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas. Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953 [TBL] [Abstract][Full Text] [Related]
4. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Wilbur DC; Barrows GH Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877 [TBL] [Abstract][Full Text] [Related]
5. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315 [TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemical characteristics of mammary carcinomas with estrogen-negative and progesterone-positive receptors]. Sundblad AS; Caprarulo L Medicina (B Aires); 1996; 56(6):683-9. PubMed ID: 9284572 [TBL] [Abstract][Full Text] [Related]
10. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors. Bozzetti C; Nizzoli R; Naldi N; Guazzi A; Camisa R; Bella MA; Cocconi G Cancer; 1999 Aug; 87(4):224-30. PubMed ID: 10455211 [TBL] [Abstract][Full Text] [Related]
11. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973 [TBL] [Abstract][Full Text] [Related]
12. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue]. Schulze MH; Buchmann J Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma. Visscher DW; Sarkar F; Tabaczka P; Crissman J Mod Pathol; 1996 Jun; 9(6):642-6. PubMed ID: 8782201 [TBL] [Abstract][Full Text] [Related]
14. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513 [TBL] [Abstract][Full Text] [Related]
15. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors. Keshgegian AA Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626 [TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251 [TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046 [TBL] [Abstract][Full Text] [Related]
19. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Cano G; Milanezi F; Leitão D; Ricardo S; Brito MJ; Schmitt FC Diagn Cytopathol; 2003 Oct; 29(4):207-11. PubMed ID: 14506673 [TBL] [Abstract][Full Text] [Related]
20. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl-2 expression, hormone receptors, and lymph node metastases. Frankfurt OS; Robb JA; Sugarbaker EV; Villa L Clin Cancer Res; 1997 Mar; 3(3):465-71. PubMed ID: 9815706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]